Eslicarbazepine acetate (ESL) is an anticonvulsant drug approved for the treatment of focal epilepsies, and related to oxcarbazepine and carbamazepine (CBZ), which are also derivatives of the dibenzazepine family. ESL is contraindicated in patients with hypersensitivity reactions to CBZ.We report a patient with frontal lobe epilepsy responding to treatment with ESL without any serious adverse effects after developing a severe skin rash following treatment with CBZ. HLA testing revealed an HLA-A*31:01 haplotype, that increases the risk of CBZ-induced cutaneous reactions.This case study shows that, in clinical practice, ESL may be considered in a patient with the HLA-A*31:01 haplotype and a hypersensitivity reaction to CBZ.
Introduction
Eslicarbazepine acetate (ESL) is an anticonvulsant drug approved for the treatment of focal epilepsies. It is related to oxcarbazepine (OXC) and carbamazepine (CBZ), which are also derivatives of the dibenzazepine family. Like OXC, ESL is metabolized into its active moiety S-licarbazepine by the liver. In contrast to CBZ, ESL lacks a toxic epoxide [1] . Rash is described as a side effect in 0.4-1.5% of patients receiving ESL and appears less common than in treatment with CBZ (1-10%) [1] . According to the official summary of product characteristics available from the European Medicines Agency (EMA, London, UK), ESL is contraindicated in patients with hypersensitivity reactions to CBZ. We report a patient with frontal lobe epilepsy responding to treatment with ESL without any serious adverse effects after developing a severe skin rash following treatment with CBZ.
Case report
A 27-year-old German woman of Pakistani descent developed focal epilepsy with non-specific auras followed by automotor seizures occurring three to six times a day. Brain MRI showed no focal lesions and there was no family history of seizures or epilepsy. An inflammatory or infectious cause of her epilepsy was ruled out by CSF examination and screening for anti-neuronal antibodies.
In accordance with German epilepsy guidelines, she was started on monotherapy with levetiracetam (max. 3000 mg/d). Due to ongoing seizures, add-on therapy with lamotrigine (max. 400 mg/ d) was initiated, and levetiracetam was later switched to brivaracetam (max. 200 mg/d). Due to the refractory course, a presurgical evaluation was performed. Video EEG monitoring revealed left-sided frontal lobe epilepsy with seizure onset at the electrodes F3/Fz/Cz. Add-on therapy with CBZ 400 mg/d was started and resulted in immediate cessation of the seizures. However, she presented with generalized maculopapular exanthema three weeks later. Blood tests showed CBZ at 6.4 mg/l (Reference range 3-12), elevated CBZ-10-11-epoxide at 5.5 mg/l (0.5-3) and slightly elevated liver enzymes. CBZ was discontinued, and the seizures recurred at the usual frequency. Due to the excellent response to CBZ, the patient wished to reinitiate CBZ or a similar compound. After considering the risks and benefits, ESL 200 mg/d was added four weeks later and gradually increased to 800 mg/d. The seizure frequency decreased markedly and the patient developed no adverse effects. In the meantime, HLA testing revealed an HLA-A*31:01 haplotype.
Discussion
This case study shows that, in clinical practice, ESL may be considered in a patient with the HLA-A*31:01 haplotype and a hypersensitivity reaction to CBZ. Unlike CBZ, ESL does not contain the epoxide derivative; hence, the chance of developing a rash is reduced [1] . Increased CBZ-epoxide levels in our patient may have been due to brivaracetam co-administration, which is known to increase CBZepoxide in a dose-dependent manner. This may be due to the negative influence of brivaracetam on epoxide hydrolase, which converts CBZ-epoxide into carbamazepine-diol [2] . The clinical significance of this interaction is not known. Brivaracetam was continued during therapy with CBZ and later with ESL.
Tolerability of ESL was similarly reported in a patient with drugresistant bipolar disorder who previously developed rashes under medication with valproate, lamotrigine, phenytoin and CBZ. He tolerated ESL without side effects. Due to his history of developing rashes, levocetirizine 5 mg/d was administered concomitantly with ESL [3] .
Testing for HLA-B*1502 or HLA-A*3101 should be considered ahead of CBZ treatment in high-risk populations and was shown to be cost-effective in the Southeast Asian population [4] . These CBZ associated risks are also discussed in depth in the ESL summary of product characteristics as outlined below. HLA-B* 1502 has a carrier prevalence of 10% among Han Chinese and Thai populations and is strongly associated with the risk of developing Stevens Johnson syndrome (SJS) on treatment with CBZ. HLA screening is usually recommended before starting treatment with CBZ or chemically-related active substances in this population [1, 4] . HLA-A*3101 was associated with an increased risk of CBZ-induced cutaneous adverse drug reactions including SJS, TEN, drug rash with eosinophilia, acute generalized exanthematous pustulosis and maculopapular rash in people of European (2%-5% carrier prevalence) and Japanese (10% carrier prevalence) descent [4] . The presence of the HLA-A*3101 allele may increase the risk of CBZinduced cutaneous reactions from 5.0% in the general population to 26.0% among subjects with European ancestry. Its absence may reduce the risk from 5.0% to 3.8% [4] .
In patients known to be positive for HLA-B*1502 or HLA-A*3101, alternative medications should be used. Due to possible crossreactivity, CBZ-related compounds such as OXC should also be avoided [4] . ESL may be considered if the benefits are thought to exceed the risks. However, the overall safety of ESL in patients with HLA-B*15:02 or HLA-A*31:01 haplotypes with a history of CBZ-or OXC-induced hypersensitivity reactions remains to be investigated in larger studies.
Conflict of Interest
L. Kay, J.P. Zöllner and P.S. Reif have nothing to disclose. L.M. Willems reports travel support from Eisai, outside the submitted work.
K.M. Klein reports personal fees from UCB Pharma, Novartis Pharma AG and Eisai as well as grants from the Deutsche Forschungsgemeinschaft and The University of Melbourne, outside the submitted work.
F. Rosenow reports personal fees from Eisai, grants and personal fees from UCB, grants and personal fees from Desitin Arzneimittel, personal fees and other from Novartis, personal fees from Medtronic, personal fees from Cerbomed, personal fees from ViroPharma and Shire, grants from European Union, grants from Deutsche Forschungsgemeinschaft, outside the submitted work.
A. Strzelczyk reports personal fees and grants from Bayer HealthCare, Boehringer Ingelheim, Desitin Arzneimittel, Eisai, LivaNova, Pfizer, Sage Therapeutics, UCB Pharma and Zogenix, outside the submitted work.
We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
